69201842-6398-4509-b227-fca5bc12b08d
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 69
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.620
- INTERFERON_GAMMA_RESPONSE+0.550
- ALLOGRAFT_REJECTION+0.460
- ANGIOGENESIS+0.450
- INFLAMMATORY_RESPONSE+0.420
- IL6_JAK_STAT3_SIGNALING+0.380
- COMPLEMENT+0.370
- APICAL_SURFACE+0.360
- MITOTIC_SPINDLE+0.270
- IL2_STAT5_SIGNALING+0.260
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.380
- MYC_TARGETS_V1-0.370
- WNT_BETA_CATENIN_SIGNALING-0.340
- DNA_REPAIR-0.330
- MYC_TARGETS_V2-0.240
- PEROXISOME-0.210
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.210
- UNFOLDED_PROTEIN_RESPONSE-0.200
- PANCREAS_BETA_CELLS-0.170
- BILE_ACID_METABOLISM-0.150
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 6d4df71e-cbf8-49e7-a511-8c8c1ea780e8 | — | — | 0.866 |
| 2 | TCGA-55-6979-01A-11R-1949-07 | — | cohortA1 | 0.859 |
| 3 | MDT-AP-3331 | Med | Medulloblastoma | 0.855 |
| 4 | c55bb20b-c929-42e2-be7f-8b1da7bee953 | — | — | 0.847 |
| 5 | MDT-AP-0363 | Med | Medulloblastoma | 0.843 |
| 6 | s_150203_5b | EPN | Posterior Fossa EPN | 0.841 |
| 7 | MDT-AP-2796 | Med | Medulloblastoma | 0.836 |
| 8 | TCGA-55-6712-01A-11R-1858-07 | — | cohortA1 | 0.832 |
| 9 | ea0e56e4-d9e3-44a2-9bdb-2e98554f6bff | — | — | 0.821 |
| 10 | SRR4296066 | — | cohortA1 | 0.821 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.620 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.550 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.460 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.450 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.420 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.380 | Inavolisib | — uncovered |
| COMPLEMENT | 0.370 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.360 | Temsirolimus | — uncovered |
| MITOTIC_SPINDLE | 0.270 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.260 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.260 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.250 | Inavolisib | — uncovered |
| APOPTOSIS | 0.240 | Idelalisib | — uncovered |
| COAGULATION | 0.230 | Binimetinib | — uncovered |
| HYPOXIA | 0.210 | Idelalisib | — uncovered |
| MYOGENESIS | 0.200 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.200 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.140 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.140 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.140 | Temsirolimus | — uncovered |